DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Avelumab is an investigational drug.
There have been 167 clinical trials for Avelumab. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2016.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Non-Small-Cell Lung, and Colorectal Neoplasms. The leading clinical trial sponsors are Pfizer, Merck KGaA, and National Cancer Institute (NCI).
There are twenty-one US patents protecting this investigational drug and six hundred and twenty international patents.
Recent Clinical Trials for Avelumab
|Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer||Institut Paoli-Calmettes||Phase 2|
|Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Horm||National Cancer Institute (NCI)||Phase 1/Phase 2|
|Intratumoral Microdosing of TAK-981 in Head and Neck Cancer||Takeda||Early Phase 1|
Top disease conditions for Avelumab
Top clinical trial sponsors for Avelumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Avelumab||See Pricing||Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers||Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)||See Pricing|
|Avelumab||See Pricing||Methods of using OX40 ligand encoding polynucleotides||ModernaTX, Inc. (Cambridge, MA)||See Pricing|
|Avelumab||See Pricing||Combinations of mRNAs encoding immune modulating polypeptides and uses thereof||ModernaTX, Inc. (Cambridge, MA)||See Pricing|
|Avelumab||See Pricing||Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors||Immunomedics, Inc. (Morris Plains, NJ)||See Pricing|
|Avelumab||See Pricing||Method of treating pancreatic cancer||ChemoCentryx, Inc. (Mountain View, CA)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Avelumab||European Patent Office||3313818||2035-06-26||See Pricing|
|Avelumab||World Intellectual Property Organization (WIPO)||2016210262||2035-06-26||See Pricing|
|Avelumab||European Patent Office||3394093||2035-12-23||See Pricing|
|Avelumab||World Intellectual Property Organization (WIPO)||2017112943||2035-12-23||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|